SOUTH SAN FRANCISCO, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that the Company will present updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC) and final results from its Phase 1 cardiac safety trial. The data from both trials will be presented at a poster session during the AACR-NCI -EORTC's "Molecular Targets and Cancer Therapeutics" International Conference in Boston. Picoplatin is a new generation platinum-based chemotherapy agent and the Company's lead product candidate.
Poster presentation details are as follows:
Randomized Phase 2 study of Picoplatin in Combination with 5-fluorouracil
and Leucovorin (FOLPI) as a Neuropathy-Sparing Alternative to mFOLFOX-6
as First-line Therapy for Colorectal Cancer (CRC)
Abstract #B49
R.L. De Jager, S. V. Cheporov, O. A. Gladkov, M. Y. Biakhov, H. B. Breitz,
R. H. Earhart, and the FOLPI Study Group
Poster Session B: Clinical Trials 2
Tuesday, November 17, 12:30-2:30 p.m. Eastern Time
Halls C-D, Hynes Convention Center
QTc Study of Picoplatin with Emphasis on Pharmacodynamics of Cardiac
Repolarization
Abstract #B212
R. H. Earhart, L. Rosen, D. Mendelson, S. Plaxe, P. Gold, L. Yee,
S. Mansoor, C. Verschraegen, A. Phillips, S. Houston, and R.L. De Jager
Poster Session B: Pharmacokinetics and Pharmacodynamics 1
Tuesday, November 17, 12:30-2:30 p.m. Eastern Time
Halls C-D, Hynes Convention Center
About Picoplatin
Picoplatin is a new and differentiated platinum-based chemotherapeutic agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration. It is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. More than 1,100 patients have received picoplatin. Results obtained to date suggest that hematologic events are common but manageable. Kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) are less frequent and less severe than is commonly observed with other platinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors.
In addition to the Phase 1 cardiac safety assessment and the Phase 2 trial in patients with colorectal cancer, Poniard is evaluating intravenous picoplatin in the pivotal Phase 3 SPEAR trial in patients with small cell lung cancer, and in a Phase 2 clinical trial in patients with castration-resistant prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors. Poniard has received both Orphan Drug designation and Fast Track designation for picoplatin for the second-line treatment of refractory or resistant SCLC from the FDA and orphan medicinal product designation for the treatment of SCLC by the European Commission.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.
(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.
SOURCE Poniard Pharmaceuticals, Inc.
